Description

Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer’s disease

Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer’s disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2012-07-16
    Resource Type
  • Text
  • Collections this item is in
    Identifier

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Hughes, A. K., Cichacz, Z., Scheck, A., Coons, S. W., Johnston, S. A., & Stafford, P. (2012). Immunosignaturing Can Detect Products from Molecular Markers in Brain Cancer. PLoS ONE, 7(7). doi:10.1371/journal.pone.0040201

    Machine-readable links